



Data Glacier

Your Deep Learning Partner

Exploratory Data Analysis

Healthcare – Persistency of a drug


12/11/2022



Data Glacier

Your Deep Learning Partner


Name	Email	Country	College/Company	Specialization
Fabian Umeh	Fabianumeh335@gmail.com	UK	Teesside University	Data Science
Rukevwe Ovuowo	rukevwe10@gmail.com	Nigeria	GBG Data science Academy	Data Science
Olutayo Oladeinbo	oladeinboolutayo@yahoo.com	UK	Teesside University	Data Science



Agenda

- Executive Summary
 - Problem Statement
 - Objectives
 - Approach
- EDA
- EDA Summary

Executive Summary



Problem statement

- One of the challenge for all Pharmaceutical companies is to understand the persistency of drugs as per the physician prescription. To solve this problem ABC pharma company would like the process Automated.

Objectives

- The overall aim of the analysis part of the project is to provide insights into factors that impact the persistency of drugs, which afterwards will lay the foundation on building a suitable classification model.

Approach




- Understanding the dataset
- Identifying the most impactful factors
- Making recommendations.

Data Understanding


data.head()											Bucket Unique Row Id	Variable Patient ID	Variable Description Unique ID of each patient
Ptid	Persistence_Flag	Gender	Race	Ethnicity	Region	Age_Bucket	Ntm_Speciality	Ntm_Specialist_Flag	Ntm_Speciality_Bucket	...	Risk_Family_History_Of	Persistence_Flag	Flag indicating if a patient was persistent or not
0	P1	Persistent	Male	Caucasian	Not Hispanic	West	>75	GENERAL PRACTITIONER	Others	OB/GYN/Others/PCP/Unknown	...	Age	Age of the patient during their therapy
1	P2	Non-Persistent	Male	Asian	Not Hispanic	West	55-65	GENERAL PRACTITIONER	Others	OB/GYN/Others/PCP/Unknown	...	Race	Race of the patient from the patient table
2	P3	Non-Persistent	Female	Other/Unknown	Hispanic	Midwest	65-75	GENERAL PRACTITIONER	Others	OB/GYN/Others/PCP/Unknown	...	Region	Region of the patient from the patient table
3	P4	Non-Persistent	Female	Caucasian	Not Hispanic	Midwest	>75	GENERAL PRACTITIONER	Others	OB/GYN/Others/PCP/Unknown	...	Ethnicity	Ethnicity of the patient from the patient table
4	P5	Non-Persistent	Female	Caucasian	Not Hispanic	Midwest	>75	GENERAL PRACTITIONER	Others	OB/GYN/Others/PCP/Unknown	...	Gender	Gender of the patient from the patient table
5 rows x 69 columns											Demographics	IDN Indicator	Flag indicating patients mapped to IDN
											Provider Attributes	NTM - Physician Specialty	Specialty of the HCP that prescribed the NTM Rx
												NTM - T-Score	T Score of the patient at the time of the NTM Rx (within 2 years prior from rxdate)
												Change in T Score	Change in Tscore before starting with any therapy and after receiving therapy (Worsened, Remained Same, Improved, Unknown)
												NTM - Risk Segment	Risk Segment of the patient at the time of the NTM Rx (within 2 years days prior from rxdate)
												Change in Risk Segment	Change in Risk Segment before starting with any therapy and after receiving therapy (Worsened, Remained Same, Improved, Unknown)
												NTM - Multiple Risk Factors	Flag indicating if patient falls under multiple risk category (having more than 1 risk) at the time of the NTM Rx (within 365 days prior from rxdate)
											Clinical Factors	NTM - Dexa Scan Frequency	Number of DEXA scans taken prior to the first NTM Rx date (within 365 days prior from rxdate)
												NTM - Dexa Scan Recency	Flag indicating the presence of Dexa Scan before the NTM Rx (within 2 years prior from rxdate or between their first Rx and Switched Rx; whichever is smaller and applicable)
												Dexa During Therapy	Flag indicating if the patient had a Dexa Scan during their first continuous therapy
												NTM - Fragility Fracture Recency	Flag indicating if the patient had a recent fragility fracture (within 365 days prior from rxdate)
												Fragility Fracture During Therapy	Flag indicating if the patient had fragility fracture during their first continuous therapy
												NTM - Glucocorticoid Recency	Flag indicating usage of Glucocorticoids (>=7.5mg strength) in the one year look-back from the first NTM Rx
												Glucocorticoid Usage During Therapy	Flag indicating if the patient had a Glucocorticoid usage during the first continuous therapy
												NTM - Injectable Experience	Flag indicating any injectable drug usage in the recent 12 months before the NTM OP Rx
												NTM - Risk Factors	Risk Factors that the patient is falling into. For chronic Risk Factors complete lookback to be applied and for non-chronic Risk Factors, one year lookback from the date of first OP Rx
											Disease/Treatment Factor	NTM - Comorbidity	Comorbidities are divided into two main categories - Acute and chronic, based on the ICD codes. For chronic disease we are taking complete look back from the first Rx date of NTM therapy and for acute diseases, time period before the NTM OP Rx with one year lookback has been applied
												NTM - Concomitancy	Concomitant drugs recorded prior to starting with a therapy(within 365 days prior from first rxdate)
												Adherence	Adherence for the therapies

- The dataset contains 3424 rows and 69 columns.

Exploratory data analysis





- The number of cases where the drugs proved to be non-persistent were higher compared to number of persistency cases.
- The dataset reveals that more females partook in this analysis than male.
- People of Caucasian race when compared to other races were the most common in the study.






- The non-Hispanic ethnic group were the most common in the study.
- There were more people from the Midwest and South region compared to other regions.


Exploratory data analysis




Exploratory data analysis




- For this study, the majority of people selected are greater than 75 years of age.
- People with a Tscore of >-2.5 have a higher chance of drug being non-persistent.



Exploratory data analysis




- The chart reveals people with a lower count of risk have a higher chance of drug being non-persistent.



Summary and recommendation

EDA SUMMARY

- The dataset contains 3424 rows and 69 columns.
- The number of cases where the drugs proved to be non-persistent were higher compared to number of persistency cases.
- The dataset reveal that more females partook in this analysis than male.
- People of Caucasian race when compared to other races were the most common in the study.
- The non-Hispanic ethnic group were the most common in the study.
- There were more people from the Midwest and South region compared to other regions.
- For this study, most people selected are greater than 75 years of age.
- People with a Tscore of >-2.5 have a higher chance of drug being non-persistent.



Repository details

- Github Repo link: [Ovuowo-Rukevwe/-Healthcare-Persistency-of-a-Drug \(github.com\)](https://github.com/Ovuowo-Rukevwe/-Healthcare-Persistency-of-a-Drug)

Thank You